Agenus to Present on Seven Novel Programs at SITC 2020
LEXINGTON, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that seven abstracts were accepted for presentation at the virtual SITC 2020 Annual Meeting from November 9-14, 2020.
Abstract title: AGEN1181, an Fc engineered anti-CTLA-4 antibody, demonstrates clinical activity, alone or in combination with balstilimab (anti-PD-1), and broadens the therapeutic potential of CTLA-4 therapy (NCT03860272)
Abstract title: Single-agent Zalifrelimab (anti-CTLA-4) Shows Clinical Benefit in Rare Tumors - Case Report from Phase 2 Study (NCT03104699)
Abstract title AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and Fc?R co-targeting to promote antitumor immunologic effects
Abstract title: Pseudoprogression Patterns: Analysis from 2 Independent Phase-2 Studies with Immunotherapy for Recurrent Cervical Cancer
Abstract title: AgenT-797, a novel allogenic and “off-the shelf” iNKT cell therapy promotes effective tumor killing
Abstract title: Anti-TIGIT antibodies require enhanced Fc?R co-engagement for optimal T and NK cell-dependent anti-tumor immunity
Abstract title: Beyond PD-L1: novel PD-1 biomarkers identified by driving T cell dysfunction in vitro
There was a premature disclosure of at least one Agenus abstract on the conference website, which reflected data that was only available at the time of abstract submission in August 2020. Updated data will be presented at the conference and will become available on the Agenus website at https://investor.agenusbio.com/events-and-presentations following the presentations on November 9-14, 2020.
Occupant Wellness in the Indoor Environment
ROI Use Case